News
VRDN
17.51
0.00%
0.00
Weekly Report: what happened at VRDN last week (0318-0322)?
Weekly Report · 3d ago
BUZZ-Immunovant and Argenx rise as rival Chugai's data fails to impress
Immunovant and Argenx rise as rival Chugai's data fails to impress. Japan-based Chugae Pharma reports late-stage data of its autoimmune disease drug satralizumab. Shares of Immunovant rise 2.5% to $32.36 and ARgenx rises 12.3%.
Reuters · 03/21 16:04
Viridian Therapeutics Is Maintained at Buy by B. Riley Securities
Dow Jones · 03/21 14:15
Viridian Therapeutics Price Target Cut to $25.00/Share From $29.00 by B. Riley Securities
Dow Jones · 03/21 14:15
B. Riley Securities Maintains Buy on Viridian Therapeutics, Lowers Price Target to $25
Benzinga · 03/21 14:05
Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Viridian Therapeutics (VRDN)
TipRanks · 03/21 10:40
Buy Rating Endorsed for Viridian Therapeutics’ VRDN Treatments Based on Superior Efficacy and Dosing Advantages in TED Market
TipRanks · 03/20 19:35
Buy Rating Affirmed for Viridian Therapeutics Amid Strong Competitive Position and Promising Drug Prospects
TipRanks · 03/20 18:35
Unveiling 4 Analyst Insights On Viridian Therapeutics
Viridian Therapeutics is a clinical-stage biopharmaceutical company developing products for thyroid eye disease. The company has an average price target of $34.25 for the next 12 months. 4 analysts have shared their insights on Viridian Therapedutics in the past three months. The average 12-month price target has decreased by 0.72%. The company is developing a product candidate for the potential treatment of thyroid disease.
Benzinga · 03/20 18:00
Viridian Therapeutics Is Maintained at Buy by Needham
Dow Jones · 03/20 17:17
Viridian Therapeutics Leads in Thyroid Eye Disease Treatments: Superior Efficacy and Promising Pipeline Justify Buy Rating
TipRanks · 03/20 17:15
Needham Maintains Buy on Viridian Therapeutics, Maintains $30 Price Target
Benzinga · 03/20 17:07
Weekly Report: what happened at VRDN last week (0311-0315)?
Weekly Report · 03/18 11:29
Weekly Report: what happened at VRDN last week (0304-0308)?
Weekly Report · 03/11 11:25
Weekly Report: what happened at VRDN last week (0226-0301)?
Weekly Report · 03/04 11:28
Analysts Anticipate ESML Will Reach $43
NASDAQ · 03/01 11:53
Buy Rating Affirmed for Viridian Therapeutics Amid Strong Clinical Progress and Market Potential
TipRanks · 03/01 06:00
Viridian Therapeutics Price Target Maintained With a $37.00/Share by HC Wainwright & Co.
Dow Jones · 02/29 20:29
HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $37 Price Target
Benzinga · 02/29 20:19
Oppenheimer Remains a Buy on Viridian Therapeutics (VRDN)
TipRanks · 02/29 13:06
More
Webull provides a variety of real-time VRDN stock news. You can receive the latest news about Viridian Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.